Cronos Group Inc.
CRONHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. At a $1.20B market cap, Cronos Group Inc. ranks as a small-cap company within healthcare. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Market Cap
$1.20B
Beta
1.28
P/E (TTM)
17.16
P/E (Fwd)
-81.50
EPS (TTM)
$0.19
EPS (Fwd)
$-0.04
ROE
7.0%
ROA
-0.1%
Cash
$797.0M
Total Debt
$1.3M
Free CF
$6.1M
52W Change
27.8%
Annual Financials
Cash vs Debt
Where CRON stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CRON finished 17.82% above its 150-day moving average ($2.75) and 19.12% above its 200-day moving average ($2.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRON overbought or oversold?
At the September 3, 2026 close, CRON's RSI(14) was 54.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cronos Group Inc. holds $797.0M in cash against $1.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $6.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 7.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $86.7M (2022) to $146.6M (2025), reflecting a 69% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cronos Group Inc. and its sector.